Trial Profile
An Open label prospective study of Sofosbuvir, Velpatasvir, voxilaprevir assessing efficacy and safety in the treatment of triple infection with Chronic Hepatitis C, Chronic Hepatitis B, and HIV
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2018
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis B; Hepatitis C; HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms SOLVVE-C
- 13 Nov 2018 New trial profile.
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases